Mabvax Therapeutics Holdings, Inc. (MBVX)

Trade MBVX now with
1/4/2019 8:09:13 AM MabVax Enters Into Discussions To Merge With Oncotelic
11/28/2018 8:05:47 AM MabVax Enters Equity Purchase Agreement With Triton Funds LP
9/21/2018 8:06:16 AM Delaware Court Of Chancery Grants Petition Filed By MabVax Therapeutics
7/3/2018 8:03:14 AM MabVax Therapeutics Grants Exclusive Sublicense To Y-mAbs Therapeutics For Patented Neuroblastoma Vaccine
7/2/2018 8:33:11 AM MabVax Decides Not To Submit Plan To Regain Compliance With Nasdaq Listing Standards
5/17/2018 8:46:58 AM MabVax Therapeutics Receives U.S. Patent For Fully Human Antibodies
4/2/2018 7:36:47 AM MabVax 2017 Net Loss $19.0 Mln Vs. Loss $17.7 Mln Prior Year
3/6/2018 9:16:39 AM MabVax Regains Compliance With NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement
2/12/2018 7:10:13 AM MabVax Says Positive Phase 1 Trial Interim Results Evaluating MVT-5873 In Combination With Care Chemotherapy
2/6/2018 7:07:05 AM MabVax Therapeutics Closes $2.1 Mln Private Placement Financing
12/20/2017 7:09:24 AM MabVax Completes Enrollment And Initial Patient Dosing In Expanded Cohort Of The Phase 1 Trial Evaluating MVT-5873
12/13/2017 7:33:59 AM MabVax Therapeutics Completes Enrollment And Dosing In Initial Cohort Of MVT-1075 Radioimmunotherapy Phase 1 Trial
11/16/2017 7:07:46 AM MabVax Therapeutics Regains Compliance With Nasdaq's Minimum Stockholders' Equity Listing Requirements